Skip to main content
Search

BRIUMVI® (ublituximab-xiiy) in the real-world setting

Real World Experience With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal Registry Study (ENABLE)

  • Clinical Trial Information

    Trial Contact: Mondragon, Diana; Carlo, Charlene S; Monserrate, Francheska; Melendez, Thomas L

    Trial Phone: 3218414717 ; 321.841.1324 ; 321-841-4717 ; 321.841.6813

  • IRB No: S24.081.07

    Protocol Abbrev: ENABLE

    Principal Investigator: Amy (Amparo) Gutierrez, MD, FAAN

    Age Group: Adult

    Secondary Protocol No: TG1101-RMS406

    ClinicalTrials.gov ID: NCT06433752

  • Objective

    The purpose of this study is to evaluate safety, effectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

  • Key Eligibility

    ≥ 18 years old, adult patients with relapsing forms of MS.
    Patients who have not received any BRIUMVI®(ublituximab-xiiy) infusion prior to enrollment.

Share: